4-(6-Bromo-2-benzothiazolyl)benzenamine_product_DataBase

Bioactivity	4-(6-Bromo-2-benzothiazolyl)benzenamine is a β-amyloid PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.
Target	β-amyloid
Invitro	4-(6-Bromo-2-benzothiazolyl)benzenamine (compound 6l) plus ultraviolet A (UVA) can induce caspase-3 activity, poly(ADP-ribose)polymerase cleavage, M30 positive CytoDeath staining, and subsequent apoptotic cell death. Treatment of A375 cells with 4-(6-Bromo-2-benzothiazolyl)benzenamine plus UVA results in a decrease in mitochondrial membrane potential (ΔΨmt), oxidative phosphorylation system (OXPHOS) subunits, and adenosine triphosphate (ATP) but an increase in mitochondrial DNA 4977-bp deletion via reactive oxygen species (ROS) generation. Transmission electron microscopy (TEM) observations also show major ultrastructural alterations of mitochondria[2].
In Vivo	4-(6-Bromo-2-benzothiazolyl)benzenamine plus UVA is shown to reduce murine melanoma size in a mouse model. 4-(6-Bromo-2-benzothiazolyl)benzenamine-PDT may serve as a potential ancillary modality for the treatment of melanoma[2].
Name	4-(6-Bromo-2-benzothiazolyl)benzenamine
CAS	566169-97-9
Formula	C13H9BrN2S
Molar Mass	305.19
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Klunk W, et al. Benzothiazole derivative compounds, compositions and uses. WO2004083195 A1 [2]. Chen YK, et al. Apoptosis induced by 2-aryl benzothiazoles-mediated photodynamic therapy in melanomas via mitochondrial dysfunction. Chem Res Toxicol. 2014 Jul 21;27(7):1187-98.

PeptideDB

4-(6-Bromo-2-benzothiazolyl)benzenamine

CAS: 566169-97-9 F: C13H9BrN2S W: 305.19